CLDX — Celldex Therapeutics, Inc.

—
Nasdaq · Health Care · Life Sciences Tools & Services · CIK 744218 ·
Last close
$28.04
Market Cap
$2.20B
52W High
$45.14
52W Low
$22.33
ADV30
1,089,357
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -82,251,000 -75,557,000 721,531,000 26,952,000 72,062,000
Jun 2026 22,000 — -80,623,000 -73,503,000 782,349,000 47,454,000 67,785,000
Mar 2026 15,000 — -84,435,000 -78,685,000 511,254,000 35,729,000 55,028,000
Dec 2025 121,000 — -87,153,000 -81,317,000 582,983,000 28,871,000 55,818,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-235,566,000
Investing CF
$-67,131,000
Financing CF
$327,107,000
CapEx
$-6,539,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.35
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,966,169,000
Inventory
—
Receivables
$230,000
ST Investments
$670,133,000
EBIT TTM
$-325,828,000
Pretax Income TTM
$-300,549,000
Interest Exp TTM
—
Analysts
14

Yahoo Snapshot (yfinance, live)

Total Revenue
$158,000
EBITDA
$-330,728,000
Free Cash Flow
$-154,987,744
Enterprise Value
$1,705,691,648
Total Cash
$650,318,976
Total Debt
$9,870,000
Shares Out
78,545,051
Trailing EPS
$-4.29
Book Value
$8.27
ROE
-49.5%
ROA
-30.5%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 1,545,000 -287,367,000 -258,757,000 582,983,000 55,818,000 527,165,000 -210,945,000
Dec 2024 7,020,000 -195,078,000 -157,863,000 792,340,000 45,335,000 747,005,000 -157,778,000
Dec 2023 6,883,000 -142,042,000 -141,429,000 465,627,000 36,456,000 429,171,000 -107,291,000
Dec 2022 2,357,000 -107,096,000 -112,325,000 352,735,000 26,531,000 326,204,000 -103,732,000

TTM Snapshot

Revenues TTM
$157,000
NetIncome TTM
$-300,549,000
OpCashFlow TTM
—
Assets (Latest)
$782,349,000
Forward EPS
$-4.21

Peers — same industry

TickerNameMarket CapLastDaily %
NEOG NEOGEN CORP $2.38B $10.90 —
NTLA Intellia Therapeutics, Inc. $1.37B $9.78 —
ABSI Absci Corp $1.31B $7.58 —
OABI OmniAb, Inc. $736.59M $5.05 —
LNTH Lantheus Holdings, Inc. $6.66B $101.80 —

News headlines (Yahoo Finance, 1h cache)

Guggenheim reiterates this biotech stock as a top pick
2026-11-10 14:10 · Yahoo
Celldex Therapeutics Targets 2027 Filing for Barzolvolimab After Phase 3 Results
2026-11-10 06:12 · Yahoo
Celldex Stock In Focus After Earnings Loss And Shelf Filing
2026-11-06 20:14 · Yahoo
Celldex: Q3 Earnings Snapshot
2026-11-05 21:26 · Yahoo
Celldex Reports Third Quarter Financial Results and Provides Corporate Update
2026-11-05 21:01 · Yahoo
Celldex to Present at Upcoming Investor Conferences
2026-11-04 21:01 · Yahoo
Celldex Therapeutics (CLDX) Stock Looks Rich After Shareholder Investigation
2026-10-17 00:15 · Yahoo
Can Celldex (CLDX) Overcome Its Heavy Burn Rate for Long-Term Success?
2026-09-23 12:41 · Yahoo
CLDX Stock Slumps 11% – This Analyst Sees Nearly 90% Upside, Calls Phase 3 Trial Safety Concerns ‘Misplaced’
2026-09-22 17:10 · Yahoo
Celldex Phase III CSU Trials Hit Endpoints as Barzolvolimab Shows Durable Responses
2026-09-22 16:02 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.